Back to top
more

Protagonist Therapeutics (PTGX)

(Delayed Data from NSDQ)

$25.15 USD

25.15
461,248

+0.49 (1.99%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $25.11 -0.04 (-0.16%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (76 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for PTGX

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Protagonist Therapeutics, Inc. [PTGX]

Reports for Purchase

Showing records 21 - 40 ( 49 total )

Company: Protagonist Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 21

11/15/2021

Daily Note

Pages: 5

Another Win for Rusfertide, This Time in Hereditary Hemochromatosis; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 5.00

Research Provided by a Third Party

Company: Protagonist Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 22

11/04/2021

Company Report

Pages: 5

Janssen Opts-Out of PTG-200 in Favor of 2nd Gen Assets as Value Proposition Remains Unchanged; Reit Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 5.00

Research Provided by a Third Party

Company: Protagonist Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 23

10/12/2021

Daily Note

Pages: 4

Rusfertide Clinical Hold Lifted With Dosing to Resume Shortly; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 5.00

Research Provided by a Third Party

Company: Protagonist Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 24

09/28/2021

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for PTGX

Provider: ValuEngine, Inc

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Protagonist Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 25

09/20/2021

Company Report

Pages: 5

FDA Clinical Hold on Rusfertide Amid Tumorigenesis in Mouse Model

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 10.00

Research Provided by a Third Party

Company: Protagonist Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 26

08/06/2021

Company Report

Pages: 5

IBS Assets Ready to Move Out From Rusfertide’s Shadow; Reiterate Buy, PT Up to $60

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 10.00

Research Provided by a Third Party

Company: Protagonist Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 27

07/29/2021

Daily Note

Pages: 3

Protagonist Scores a Big Win as Janssen Looks to Accelerate IL-23 Franchise; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 10.00

Research Provided by a Third Party

Company: Protagonist Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 28

06/18/2021

Company Report

Pages: 8

Update from EHA: Rusfertide’s Impressive Phase 2 Data Shown to Be Durable; Reit Buy Raise PT to $48

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 25.00

Research Provided by a Third Party

Company: Protagonist Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 29

06/18/2021

Company Report

Pages: 8

Update from EHA: Rusfertide’s Impressive Phase 2 Data Shown to Be Durable; Reit Buy Raise PT to $50

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 25.00

Research Provided by a Third Party

Company: Protagonist Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 30

05/06/2021

Company Report

Pages: 5

Rusfertide and IBS Assets Chugging Along in Clinical Trials; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 10.00

Research Provided by a Third Party

Company: Protagonist Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 31

03/23/2021

Daily Note

Pages: 4

Protagonist Gets Green Light for Single International PV Phase 3 from FDA and EMA; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 10.00

Research Provided by a Third Party

Company: Protagonist Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 32

03/11/2021

Company Report

Pages: 5

Quietly Advancing on All Fronts in the Pipeline; Reiterate Buy, PT to $36

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 10.00

Research Provided by a Third Party

Company: Protagonist Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 33

12/10/2020

Daily Note

Pages: 6

Investigator Call Provides Additional Insight on Positive PTG-300 Data Presented at ASH; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 25.00

Research Provided by a Third Party

Company: Protagonist Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 34

12/07/2020

Daily Note

Pages: 7

Update From ASH: PTG-300 Phase 2 Continues to Demonstrate Long-Term Efficacy in PV; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 25.00

Research Provided by a Third Party

Company: Protagonist Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 35

11/05/2020

Company Report

Pages: 8

PTG-300 Continues to Impress in PV With More Data in Abstracts Ahead of ASH; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 25.00

Research Provided by a Third Party

Company: Protagonist Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 36

10/30/2020

Daily Note

Pages: 3

Janssen Partnership Grows With Two New Molecules Set to Enter the Clinic; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 10.00

Research Provided by a Third Party

Company: Protagonist Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 37

09/18/2020

Company Report

Pages: 6

An Update on the PTG-300 Opportunity; Reiterate Buy, Raise Price Target to $33

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 25.00

Research Provided by a Third Party

Company: Protagonist Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 38

08/10/2020

Company Report

Pages: 5

Protagonist Makes Steady Progress on the Pipeline From a Strong Cash Position; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 10.00

Research Provided by a Third Party

Company: Protagonist Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 39

06/18/2020

Daily Note

Pages: 3

PTG-300 Offers Further Evidence of Mechanism; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 10.00

Research Provided by a Third Party

Company: Protagonist Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 40

05/18/2020

Company Report

Pages: 5

PTG-300 Comes up Aces in Polycythemia Vera; Reiterate Buy, Target up to $28

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 10.00

Research Provided by a Third Party